Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset in Refractory Systemic Sclerosis
JOURNALS
Start Learning
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis
endoscopic procedure duodenum
JOURNALS
Start Learning
Novel strategy shows potential to reduce insulin dependence in type 2 diabetes
Pancreatitis: The Abdominal Pain and Nausea of Pancreas Inflammation - Visualize a scene where abdominal pain is severe and accompanied by nausea, indicating pancreatitis, inflammation of the pancreas
JOURNALS
Start Learning
B-cell depleting agent reduces risk of flares and increases chance of remission in IgG4-RD
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025 severe allergic reactions, including anaphylaxis
JOURNALS
Start Learning
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025
Advancing Vasculitis Care and Medical Education: An Interview with Future Leader, Dr Brian Jaros
JOURNALS
Start Learning
Advancing Vasculitis Care and Medical Education: An Interview with Future Leader, Dr Brian Jaros
CONFERENCE HUB
Start Learning
The STENOVA Trial, a First-in-Class, First-in-Indication Study of AGMB-129 in Fibrostenotic Crohn’s Disease: Florian Rieder, DDW 2025
JOURNALS
Start Learning
Breakthroughs in MASH: Highlights from EASL 2024
JOURNALS
Start Learning
New study reveals elevated cognitive impairment risk in rheumatoid arthritis patients, linked to inflammation and comorbidities
www.touchimmunology.com
JOURNALS
Start Learning
FDA approves bimekizumab for psoriatic arthritis, ankylosing spondylitis and axSpA
touchEXPERT BRIEFING
Start Learning
UCB, making a difference in immunology
Sponsored content

to view Favourites, Keep Notes and Track CME Credits

Favourites
B-cell depleting agent reduces risk of flares and increases chance of remission in IgG4-RD
View
Key data on pain and prognosis: Clinical insights and implications
View
Hypermobility Spectrum Disorders and Pain: A Review of Recent Developments and their Application to Clinical Practice 
View
Medics For Rare Disease – New Year, New Strategy
View
RGB-19 Matches Tocilizumab in Efficacy and Safety: Promising Phase III Data from RA Biosimilar Trial
View
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
View
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Muhammad Nisar, BSR 2025
View
Breakthroughs in MASH: Highlights from EASL 2024
View
Bimekizumab Shows Comparable One-Year Efficacy in Male and Female axSpA Patients in Phase III BE MOBILE Trials
View
New study reveals elevated cognitive impairment risk in rheumatoid arthritis patients, linked to inflammation and comorbidities
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup